Royalty Pharma plc (RPRX) concluded trading on Thursday at a closing price of $30.03, with 3.56 million shares of worth about $106.99 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 1.15% during that period and on Thursday the price saw a gain of about 2.49%. Currently the company’s common shares owned by public are about 443.17M shares, out of which, 381.08M shares are available for trading.
However, the stock later moved at a day high price of 30.85, or with a gain of 2.49%. Stock saw a price change of 4.63% in past 5 days and over the past one month there was a price change of 6.00%. Year-to-date (YTD), RPRX shares are showing a performance of 6.91% which decreased to -20.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $25.92 but also hit the highest price of $38.51 during that period. The average intraday trading volume for Royalty Pharma plc shares is 2.57 million. The stock is currently trading 3.77% above its 20-day simple moving average (SMA20), while that difference is up 5.55% for SMA50 and it goes to 1.67% higher than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 443.17M outstanding shares and institutions hold larger chunk of about 67.03% of that.
The stock has a current market capitalization of $13.48B and its 3Y-monthly beta is at 0.43. PE ratio of stock for trailing 12 months is 75.04, while it has posted earnings per share of $0.40 in the same period. Its PEG reads 23.45 and has Quick Ratio of 13.51 while making debt-to-equity ratio of 1.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 2.63% while standing at 2.62% over the month.
Analysts are in expectations that Royalty Pharma plc (RPRX) stock would likely to be making an EPS of $1.01 in the current quarter, while forecast for next quarter EPS is $0.91 and it is $3.68 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.92 which is $1.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $1.56 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 101.26% while it is estimated to increase by 15.79% in next year. EPS is likely to grow at an annualized rate of 3.20% for next 5-years, compared to annual growth of -45.28% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 14, 2022 offering a Buy rating for the stock and assigned a target price of $47 to it.
